Editorial comment: mixing tenofovir with other nephrotoxins--how safe is this?
Gupta
Samir K
SK
Division of Infectious Diseases, Indiana University School of Medicine, Indianapolis, Indiana, USA.
D058186:Acute Kidney Injury / Q000139:chemically induced*; D000225:Adenine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects*; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D063065:Organophosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D013203:Staphylococcal Infections / Q000188:drug therapy; D000068698:Tenofovir; D014640:Vancomycin / Q000008:administration & dosage / Q000009:adverse effects*
D000900:Anti-Bacterial Agents; D019380:Anti-HIV Agents; D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors; D014640:Vancomycin; D000068698:Tenofovir; D000225:Adenine